Sign in Subscribe

Wolfe Research Upgrades Janux Therapeutics to Outperform on Upcoming Autoimmune Data

Wolfe Research upgrades Janux Therapeutics to Outperform with a $23 target. Q4 autoimmune data for JANX011 cited as key catalyst, 32% upside.

Wolfe Research Upgrades Janux Therapeutics to Outperform on Upcoming Autoimmune Data
"ARM technology platform." Credit: Janux Therapeutics
Already have an account? Sign in.